Mutual of America Capital Management LLC Sells 1,338 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Mutual of America Capital Management LLC lessened its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 177,350 shares of the biopharmaceutical company’s stock after selling 1,338 shares during the period. Mutual of America Capital Management LLC’s holdings in Halozyme Therapeutics were worth $8,479,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in HALO. Louisiana State Employees Retirement System lifted its position in Halozyme Therapeutics by 0.6% during the fourth quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company’s stock valued at $1,688,000 after purchasing an additional 200 shares during the period. Verdence Capital Advisors LLC lifted its position in Halozyme Therapeutics by 1.9% during the third quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company’s stock valued at $757,000 after purchasing an additional 252 shares during the period. State of New Jersey Common Pension Fund D lifted its position in Halozyme Therapeutics by 0.6% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company’s stock valued at $2,279,000 after purchasing an additional 302 shares during the period. Parkside Financial Bank & Trust lifted its position in Halozyme Therapeutics by 21.8% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 322 shares during the period. Finally, Nations Financial Group Inc. IA ADV lifted its position in Halozyme Therapeutics by 2.4% during the fourth quarter. Nations Financial Group Inc. IA ADV now owns 14,062 shares of the biopharmaceutical company’s stock valued at $672,000 after purchasing an additional 328 shares during the period. Institutional investors own 97.79% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on HALO. Wells Fargo & Company lowered their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. HC Wainwright increased their price objective on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. Piper Sandler increased their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. Finally, Benchmark reiterated a “buy” rating and issued a $75.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $62.78.

Insider Transactions at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the sale, the senior vice president now directly owns 173,756 shares of the company’s stock, valued at $10,126,499.68. This represents a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the sale, the director now directly owns 38,611 shares of the company’s stock, valued at approximately $2,173,799.30. This trade represents a 11.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 26,697 shares of company stock valued at $1,461,001 over the last three months. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO opened at $59.15 on Monday. The firm has a fifty day moving average price of $54.53 and a 200-day moving average price of $54.74. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The stock has a market cap of $7.28 billion, a PE ratio of 17.24, a price-to-earnings-growth ratio of 0.42 and a beta of 1.25. Halozyme Therapeutics, Inc. has a 1 year low of $37.73 and a 1 year high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. The firm had revenue of $298.01 million during the quarter, compared to analysts’ expectations of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. Equities analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.